RU2013127881A - APPLICATION OF THE PHARMACEUTICAL COMPOSITION BASED ON THE SALT OF QUATERNARY PHOSPHONY AND SUBSTITUTED DINITROBENZOFUROXAN FOR THE TREATMENT OF Pyroplasmosis in Dogs and the Method of Treatment - Google Patents

APPLICATION OF THE PHARMACEUTICAL COMPOSITION BASED ON THE SALT OF QUATERNARY PHOSPHONY AND SUBSTITUTED DINITROBENZOFUROXAN FOR THE TREATMENT OF Pyroplasmosis in Dogs and the Method of Treatment Download PDF

Info

Publication number
RU2013127881A
RU2013127881A RU2013127881/15A RU2013127881A RU2013127881A RU 2013127881 A RU2013127881 A RU 2013127881A RU 2013127881/15 A RU2013127881/15 A RU 2013127881/15A RU 2013127881 A RU2013127881 A RU 2013127881A RU 2013127881 A RU2013127881 A RU 2013127881A
Authority
RU
Russia
Prior art keywords
treatment
pyroplasmosis
dogs
pharmaceutical composition
salt
Prior art date
Application number
RU2013127881/15A
Other languages
Russian (ru)
Other versions
RU2548720C2 (en
Inventor
Ирина Васильевна Галкина
Юлия Валерьевна Бахтиярова
Светлана Николаевна Егорова
Луиза Магдануровна Юсупова
Найля Ахметовна Лутфуллина
Айрат Минсагитович Идрисов
Владимир Иванович Галкин
Минсагит Хайруллович Лутфуллин
Original Assignee
Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) Федеральный Университет" (ФГАОУ ВПО КФУ)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) Федеральный Университет" (ФГАОУ ВПО КФУ) filed Critical Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) Федеральный Университет" (ФГАОУ ВПО КФУ)
Priority to RU2013127881/15A priority Critical patent/RU2548720C2/en
Publication of RU2013127881A publication Critical patent/RU2013127881A/en
Application granted granted Critical
Publication of RU2548720C2 publication Critical patent/RU2548720C2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1. Применение фармацевтической композиции, содержащей н-тетрадецилтри-н-бутилфосфоний хлорид и 5,7-бис-(м-нитроанилино)-4,6-нитробензофуроксан в качестве активных компонентов при их весовом соотношении 1:10 и глюкозу как вспомогательное вещество, в качестве антипироплазмозного препарата для лечения пироплазмоза у собак.2. Способ по п.1, отличающийся тем, что препарат применяют перорально, два раза с интервалом 24 ч в дозе 350 мг/кг живого веса или 4 мг/кг в пересчете на действующее вещество - соль фосфония.1. The use of a pharmaceutical composition containing n-tetradecyltri-n-butylphosphonium chloride and 5,7-bis- (m-nitroanilino) -4,6-nitrobenzofuroxan as active components in a weight ratio of 1:10 and glucose as an excipient, as an anti-pyroplasmosis drug for treating pyroplasmosis in dogs. 2. The method according to claim 1, characterized in that the drug is administered orally, twice every 24 hours at a dose of 350 mg / kg live weight or 4 mg / kg in terms of the active substance - phosphonium salt.

Claims (2)

1. Применение фармацевтической композиции, содержащей н-тетрадецилтри-н-бутилфосфоний хлорид и 5,7-бис-(м-нитроанилино)-4,6-нитробензофуроксан в качестве активных компонентов при их весовом соотношении 1:10 и глюкозу как вспомогательное вещество, в качестве антипироплазмозного препарата для лечения пироплазмоза у собак.1. The use of a pharmaceutical composition containing n-tetradecyltri-n-butylphosphonium chloride and 5,7-bis- (m-nitroanilino) -4,6-nitrobenzofuroxan as active components in a weight ratio of 1:10 and glucose as an excipient, as an anti-pyroplasmosis drug for treating piroplasmosis in dogs. 2. Способ по п.1, отличающийся тем, что препарат применяют перорально, два раза с интервалом 24 ч в дозе 350 мг/кг живого веса или 4 мг/кг в пересчете на действующее вещество - соль фосфония. 2. The method according to claim 1, characterized in that the drug is administered orally, twice every 24 hours at a dose of 350 mg / kg live weight or 4 mg / kg in terms of the active substance - phosphonium salt.
RU2013127881/15A 2013-06-18 2013-06-18 Application of pharmaceutical composition, based on salt of qurternary phosphonium and substituted dinitrobenzofuroxane for treatment of piroplasmosis in dogs and treatment method RU2548720C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2013127881/15A RU2548720C2 (en) 2013-06-18 2013-06-18 Application of pharmaceutical composition, based on salt of qurternary phosphonium and substituted dinitrobenzofuroxane for treatment of piroplasmosis in dogs and treatment method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013127881/15A RU2548720C2 (en) 2013-06-18 2013-06-18 Application of pharmaceutical composition, based on salt of qurternary phosphonium and substituted dinitrobenzofuroxane for treatment of piroplasmosis in dogs and treatment method

Publications (2)

Publication Number Publication Date
RU2013127881A true RU2013127881A (en) 2014-12-27
RU2548720C2 RU2548720C2 (en) 2015-04-20

Family

ID=53278415

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013127881/15A RU2548720C2 (en) 2013-06-18 2013-06-18 Application of pharmaceutical composition, based on salt of qurternary phosphonium and substituted dinitrobenzofuroxane for treatment of piroplasmosis in dogs and treatment method

Country Status (1)

Country Link
RU (1) RU2548720C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2750798C1 (en) * 2020-10-26 2021-07-02 Общество с ограниченной ответственностью "ФАРМАЦЕЯ" Antinematodosis composition for veterinary medicine and method for its preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2347558C2 (en) * 2006-06-01 2009-02-27 Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии имени Я.Р. Коваленко (ВИЭВ) Medication for treatment of dog's pyroplasmosis
RU2473334C2 (en) * 2010-11-10 2013-01-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) Федеральный Университет" (ФГАОУ ВПО КФУ) Anti-eimeriosis pharmaceutical composition based on salt of quarternary phosphonium and substituted dinitrobenzofuroxane

Also Published As

Publication number Publication date
RU2548720C2 (en) 2015-04-20

Similar Documents

Publication Publication Date Title
CY1119490T1 (en) PYRAZOLOPYROLIDINE PRODUCTS AND THEIR USE IN PATIENT TREATMENT
EA201592256A1 (en) DERIVATIVES OF IMIDAZOPIRROLIDINONE AND THEIR APPLICATION IN THE TREATMENT OF DISEASES
EA201691151A1 (en) CONNECTIONS FOR THE TREATMENT OF PATIENTS WITH ROS1-MUTANT CANCER CELLS
EA201692280A1 (en) CONNECTIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY
EA201690069A1 (en) THE USE OF HIGH DOSE PRIDOPIDINE FOR THE TREATMENT OF THE HANTINGTON'S DISEASE
EA201891103A1 (en) COMPOSITIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY
EA201690287A1 (en) 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY
TR201904455T4 (en) 1,2,4-triazoles and their uses as nuclear transport modulators.
EA201590371A1 (en) 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS
UA114907C2 (en) Heterocyclyl compounds as mek inhibitors
EA201592255A1 (en) DERIVATIVES OF PYRAZOLOPIRROLIDIN-4-IT AS A BET INHIBITOR AND THEIR APPLICATION IN THE TREATMENT OF THE DISEASE
EA201591363A1 (en) TIADIAZOLE ANALOGUES AND METHODS OF TREATMENT OF STATES ASSOCIATED WITH SMN DEFICIENCY
EA201791727A1 (en) 7-BENZYL-4- (2-METHYLBENZIL) -2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A] PYRIDO [3,4-E] PYRIMIDIN-5 (1H) -OH, ITS ANALOGUES AND SALTS AND METHODS OF THEIR APPLICATION IN THERAPY
EA201592254A1 (en) DERIVATIVES OF Pyrazolopyrrolidin-4-IT and THEIR APPLICATION IN THE TREATMENT OF DISEASE
EA201591512A9 (en) Boron-containing molecules, methods and compositions
EA201201658A1 (en) DERIVATIVES OF PIPERIDINE AND THEIR APPLICATION FOR THE TREATMENT OF METABOLIC DISORDERS
EA201600434A1 (en) APPLICATION OF DERIVATIVES OF BENZIMIDAZOLPROLINE
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
EA201591649A1 (en) COMPOSITIONS WITH ORGANIC COMPOUNDS
EA201490045A1 (en) DEUTERED 1-PIPERAZINO-3-PHENYLINDANES USED TO TREAT SCHIZOPHRENIA
EA201690974A1 (en) HYDROMORPHONE AND NALOXONE FOR THE TREATMENT OF PAIN AND OPIOID-INITIATED INTESTINAL DYSFUNCTION SYNDROME
EA201590474A1 (en) PHARMACEUTICAL COMPOSITION BASED ON COMPOSITE CAPSULES INCLUDING IRBESARTAN AND HMG-COA REDUCTASE INHIBITOR
EA201691058A1 (en) DERIVATIVES OF PYRROLOPIRROLON AND THEIR APPLICATION FOR THE TREATMENT OF DISEASES
UA109544C2 (en) PHARMACEUTICAL COMPOSITION CONTAINING PARACETAMOL AND METHOD OF MANUFACTURING